YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors; Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

Media coverage

• Title	YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors; Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.
  Media name/outlet	CancerNetwork
  Country/Territory	United States
  Date	7/07/25
  Persons	Jennifer Yang

• Title	YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors
  Media name/outlet	Cancernetwork.com
  Country/Territory	United States
  Date	7/07/25
  URL	https://www.cancernetwork.com/view/yl201-demonstrates-tolerability-early-efficacy-in-advanced-solid-tumors
  Persons	Jennifer Yang